FOSTER CITY, Calif., Nov. 7 /PRNewswire / -- Cell Genesys, Inc. (Nasdaq : CEGE) today announced that Malcolm J. McKay
, Ph.D. has joined the company in the new position of vice president, quality and regulatory affairs.Dr. McKay
, who brings over sixteen years of regulatory affairs, quality control and product development experience to Cell Genesys, served most recently as vice president, regulatory affairs at Celtrix Pharmaceuticals, a company which was recently acquired by Insmed, Inc.
, 44, previously with Celtrix Pharmaceuticals, has also held various management positions in the regulatory affairs and quality assurance areas with other biotechnology companies including COR Therapeutics, Berlex Biosciences and Triton Biosciences.Dr. McKay
holds a Ph.D. in biochemistry from the University of London and a B.S. in biology from the University of Portsmouth in Hampshire, UK.Dr. McKay
will be assuming the management of the regulatory affairs function from Dale G. Ando, M.D., vice president of clinical research, who will now focus on the management of the company's rapidly expanding clinical trial programs.Cell Genesys currently has three GVAX (R) cancer vaccine clinical trials under way and expects to launch multiple additional trials for GVAX (R) cancer vaccines and hemophilia gene therapy during the next year.